Indeed, NF-κB has been shown to reduce mitochondrial oxidative metabolism in sarcoma cells and MAPK1/2 have been shown to promote glycolytic shift in some cancer types, as well as in rapidly proliferating cells (61, 62). The gene discussed is NFKB1; the disease is sarcoma.